Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) delivers innovative spinal implant technologies focused on minimally invasive surgical solutions and regenerative approaches. This news hub provides investors and healthcare professionals with essential updates on the company’s financial developments, product milestones, and clinical advancements.
Access timely announcements including quarterly earnings reports, regulatory approvals for new devices, and strategic partnerships within the medical device sector. Our curated collection ensures transparent tracking of Aurora Spine’s progress in improving spinal care through screwless implant systems and biointegrated solutions.
Discover press releases covering FDA clearances, research collaborations, and executive leadership changes that shape the company’s trajectory. All content is verified for accuracy and relevance to support informed decision-making about ASAPF’s market position and technological contributions.
Bookmark this page for streamlined access to Aurora Spine’s latest developments in spinal healthcare innovation. Check regularly for updates on patent filings, clinical trial results, and industry recognition of their patient-focused medical devices.
Aurora Spine Corporation has received a 'Notice of Allowance' from the USPTO for its patent on the ZIPFlex, a minimally invasive interspinous implant. This innovation aims to enhance spinal surgery outcomes by allowing for either motion preservation or fusion during operations. CEO Trent Northcutt emphasized the patent's potential to differentiate the company in the market and increase shareholder value. The new product aims to fill a significant gap in spine surgery tools, reflecting Aurora's commitment to innovative solutions.
Aurora Spine Corporation (OTCQB: ASAPF) announced the successful completion of its first anterior cervical discectomy and fusion procedures using the proprietary APOLLO Anterior Cervical Plate (ACP) system. Conducted by Dr. Sebastian Koga, these procedures highlight the system's innovative design and functionality, emphasizing its potential to enhance surgical outcomes. The APOLLO system includes advanced features like Hyper-Angulation™ screws and a titanium alloy construction. This launch marks a strategic milestone as the company prepares to introduce additional products under its DEXA Technology platform.
Aurora Spine Corporation (OTCQB: ASAPF) announced a peer-reviewed clinical publication focused on its DEXA-C spinal interbody implant. The article highlights the implant’s design, which simulates human bone structure and addresses the needs of patients with varying bone mineral density, including osteoporosis. This technology aims to improve surgical outcomes by offering personalized solutions for spinal fusion surgeries. Aurora plans to continue research and is set to begin implanting DEXA-C shortly, signaling a potential innovation in the spinal implant market.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. The company will host a webcasted Fireside Chat on December 13 at 11:00 am ET, discussing its vision for 2022, and will conduct one-on-one virtual investor meetings. Interested parties can watch the webcast on Aurora Spine's website or via a provided link. The company specializes in innovative spinal surgery devices aimed at improving surgical outcomes.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) has partnered with PRIA Healthcare to improve patient access to its innovative spinal devices, including ZIP® and SiLO™. PRIA brings 10 years of medtech experience, assisting companies in navigating insurance systems to facilitate patient access to emerging medical technologies. Aurora's leadership expresses confidence in PRIA's capabilities, emphasizing a shared commitment to enhancing patient outcomes through advanced medical solutions.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will participate in the Lytham Partners Fall 2021 Investor Conference from October 5-7, 2021. The President and CEO, Trent Northcutt, is set to present on October 5 at 2:45 PM ET. A webcast of the presentation will be accessible on the company’s website, and it will be archived for later viewing. Northcutt, along with CFO Chad Clouse, will also hold one-on-one meetings during the event. The company focuses on innovative spinal implant technologies and is anticipating commercialization of new products in the upcoming quarters.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation at the 2021 North American Spine Society Annual Meeting from September 29 to October 2, 2021, in Boston, Massachusetts. The company will showcase its FDA-cleared DEXA-C anterior fusion cages and SiLO™ SI Fusion System, designed for spinal surgery. Aurora's CEO emphasized growing adoption of their products post-COVID, particularly the innovative DEXA technology aimed at improving patient outcomes.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) has successfully closed its private placement, raising C$6,508,139.40 by issuing 11,220,930 common shares and warrants. Each warrant allows the purchase of a common share at C$0.75, maturing three years from the closing date. The funds will be allocated for sales, marketing, R&D, and working capital. A.G.P./Alliance Global Partners acted as the exclusive placement agent, receiving a 7% cash commission and broker warrants.
Aurora Spine Corporation (TSXV: ASG; OTCQB: ASAPF) announced a private placement to raise approximately C$6.5 million through the issuance of up to 11,220,930 common shares and warrants. The shares and warrants will be sold at C$0.58 each, with warrants allowing the purchase of additional shares at C$0.75 before three years. The private placement, expected to close around September 17, 2021, is subject to regulatory approvals. A.G.P./Alliance Global Partners is the exclusive placement agent in the U.S., and a 7% cash commission will be paid to them.
Aurora Spine Corporation (ASAPF) announced the enrollment of initial patients in a pivotal multi-center study for its ZIP® Interspinous Fixation device, targeting back pain due to degenerative disc disease. The REFINE Screwless™ ZIP Study aims to evaluate the device across 10 surgical sites in the US with an expected enrollment of approximately 100 patients. This minimally invasive alternative to traditional spinal surgery promises reduced recovery time and increased patient mobility. The ZIP System, cleared by the FDA in 2013, has been used in over 5,000 procedures globally, demonstrating its safety and effectiveness.
